Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
- Alzheimer's Disease (AD)
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Peking University First Hospital
- Enrolment target
- 200
- Started
- 19 March 2025
- Main results due
- 31 August 2027
- Study sites
- 1
- Registry updated
- 29 September 2026
Can you take part?
- Aged 50 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Male or female participants aged ≥ 50 years; * Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN); * Signed informed consent form Exclusion Criteria: * Presence of other neurological disorders and systemic diseases that may cause cognitive impairment; * Inability to cooperate with cognitive assessments; * Refusal to undergo blood sampling.
What this study is about
In the sponsor’s own words, from the registry.
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
Study sites(1)
Peking University First Hospital
Beijing, China
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06924359. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me